Patient navigation may lead to better breast cancer care in high risk and minority women

Patient navigation, or the linking of a newly diagnosed cancer patient with a professional trained in assisting patients though the complex journey of cancer diagnosis and treatment, may lead to better breast cancer care in high risk and minority women. The findings, recently published in the Journal of Clinical Oncology, is the first national study to show a relationship between navigators and the initiation of certain recommended treatments in breast cancer.

Using data from a previously published, multi-center study funded by the National Cancer Institute, researchers aimed to identify the possible benefits of assigning patient navigators to women recently diagnosed with breast cancer. According to the results, women were more likely to start recommended treatment when assisted by one of these trained specialists. For example, they were more likely to start hormonal therapy, which is considered the gold standard in treatment for certain types of breast cancer.

Naomi Ko, MD, MPH, instructor of medicine in the Section of Hematology Oncology at Boston University School of Medicine and a practicing breast oncologist at Boston Medical Center, stresses the need for further investigation. "This study gave us a glimpse of the potential benefit of patient navigation but there's a lot more research to be done. At this point we still need to understand how or why patient navigation works. Understanding where patient navigation is most beneficial in cancer care, in order to help the neediest patients, is a rich topic for future research," said Ko.

Navigators are experts in helping patients overcome the numerous obstacles they face, including monetary difficulties, transportation issues, educational and even language barriers, and have become an integral part of the cancer care model. It has been known that minority and high risk patients, or those who may benefit most from these navigators, often have worse outcomes after diagnosed with cancer.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Scientists map cancer mutations in EGFR gene, revealing drug resistance paths